Qizhi Jiangtang capsules treatment of early diabetic nephropathy Clinical observation of 34 cases of.doc
- 1、本文档共4页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Qizhi Jiangtang capsules treatment of early diabetic nephropathy Clinical observation of 34 cases of
PAGE \* MERGEFORMAT 4
Qizhi Jiangtang capsules treatment of early diabetic nephropathy Clinical observation of 34 cases of
Author: Rao Zu-Hua Yu Ying Pang Xiaohong REN Yue-zhong Li Xiaoqing
[Keywords:] Diabetic nephropathy
Diabetic nephropathy (diabetic nephropathy, DN) in diabetes (diabetes mellitus, DM) common and severe microvascular complications of diabetes is also one of the leading causes of death. Once the clinical proteinuria in patients with DN, it is difficult to reverse, so early treatment of DN. Is of great clinical significance. Currently angiotensin-converting enzyme inhibitors (ACEI) and its receptor antagonist (ARB) on diabetic nephropathy to a certain extent, by using traditional Chinese medicine preparation Qizhi Jiangtang DN capsule in treating 34 cases of early stage patients achieved good effect, reported as follows.
1 Data and methods
1.1 General Information
From September 2006 to December 2007, hospital outpatient and hospitalization of 65 patients with early DN patients were randomly divided into two groups. The treatment group 34 cases, male 24 cases, female 10 cases; aged 45 to 71 years, the average (54.6 ± 7.5) years of age; course of 4 to 21 years, the average (10.5 ± 5.8) years; control group, 31 cases, male 20 cases, and 11 females; aged 43 to 74 years old. Average (55.2 ± 8.1) years of age; course of 3 to 24 years, the average (11.3 ± 6.7) years. Diagnostic criteria: diagnosis of type 2 diabetes in line with WHO (1999) standards, and in accordance with Mogensen, etc. phased approach to determine the DN stage Ⅲ , that is, within 6 months for at least two more times urinary albumin excretion rate (UAER) in 2O ~ 200μ g / min between. Exclusion criteria: primary kidney disease, severe cardiovascular and liver disease, 18 years of age, or pregnant and lactating women, infection or fever, cancer patients. Do not meet the inclusion criteria: not in accordance with the provisions of drugs or medication dissatisfaction with tre
您可能关注的文档
- Purple Sin cancer capsule Acute Toxicity Test.doc
- Purpura Clinical analysis of 49 cases.doc
- Purpura clinical study of 56 cases.doc
- Purpura nephritis in children and platelet levels of fibrinogen and its clinical significance.doc
- Purpura Nephritis in Children on the diagnosis and treatment experience of 36 cases.doc
- Purslane active ingredient extraction and quantitative analysis of.doc
- Purpura 40 cases.doc
- Purslane active ingredient in vivo anticancer effects of the initial screening.doc
- Purslane and biological activities of flavonoids extracted_0.doc
- Purslane beet red pigment of anti-tumor experiment.doc
文档评论(0)